Literature DB >> 26296386

RHOA mutation may be associated with diffuse-type gastric cancer progression, but is it gain or loss?

Masahiro Maeda1,2, Toshikazu Ushijima3.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26296386     DOI: 10.1007/s10120-015-0525-9

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


× No keyword cloud information.
  10 in total

1.  Metabolism unhinged: IDH mutations in cancer.

Authors:  John R Prensner; Arul M Chinnaiyan
Journal:  Nat Med       Date:  2011-03       Impact factor: 87.241

2.  Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.

Authors:  Miwako Kakiuchi; Takashi Nishizawa; Hiroki Ueda; Kengo Gotoh; Atsushi Tanaka; Akimasa Hayashi; Shogo Yamamoto; Kenji Tatsuno; Hiroto Katoh; Yoshiaki Watanabe; Takashi Ichimura; Tetsuo Ushiku; Shinichi Funahashi; Keisuke Tateishi; Ikuo Wada; Nobuyuki Shimizu; Sachiyo Nomura; Kazuhiko Koike; Yasuyuki Seto; Masashi Fukayama; Hiroyuki Aburatani; Shumpei Ishikawa
Journal:  Nat Genet       Date:  2014-05-11       Impact factor: 38.330

3.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

Review 4.  Rho GTPase function in tumorigenesis.

Authors:  R Karlsson; E D Pedersen; Z Wang; Cord Brakebusch
Journal:  Biochim Biophys Acta       Date:  2009-03-24

5.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

6.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

7.  RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases.

Authors:  Tetsuo Ushiku; Shumpei Ishikawa; Miwako Kakiuchi; Atsushi Tanaka; Hiroto Katoh; Hiroyuki Aburatani; Gregory Y Lauwers; Masashi Fukayama
Journal:  Gastric Cancer       Date:  2015-04-01       Impact factor: 7.370

8.  Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.

Authors:  Kai Wang; Siu Tsan Yuen; Jiangchun Xu; Siu Po Lee; Helen H N Yan; Stephanie T Shi; Hoi Cheong Siu; Shibing Deng; Kent Man Chu; Simon Law; Kok Hoe Chan; Annie S Y Chan; Wai Yin Tsui; Siu Lun Ho; Anthony K W Chan; Jonathan L K Man; Valentina Foglizzo; Man Kin Ng; April S Chan; Yick Pang Ching; Grace H W Cheng; Tao Xie; Julio Fernandez; Vivian S W Li; Hans Clevers; Paul A Rejto; Mao Mao; Suet Yi Leung
Journal:  Nat Genet       Date:  2014-05-11       Impact factor: 38.330

9.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

10.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

  10 in total
  4 in total

1.  MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells.

Authors:  Alireza Korourian; Raheleh Roudi; Ahmad Shariftabrizi; Zahra Madjd
Journal:  Exp Biol Med (Maywood)       Date:  2017-08-24

2.  ARHGAP-RhoA signaling provokes homotypic adhesion-triggered cell death of metastasized diffuse-type gastric cancer.

Authors:  Masayuki Komatsu; Hitoshi Ichikawa; Fumiko Chiwaki; Hiromi Sakamoto; Rie Komatsuzaki; Makoto Asaumi; Kazuhisa Tsunoyama; Takeo Fukagawa; Hiromichi Matsushita; Narikazu Boku; Keisuke Matsusaki; Fumitaka Takeshita; Teruhiko Yoshida; Hiroki Sasaki
Journal:  Oncogene       Date:  2022-09-20       Impact factor: 8.756

3.  Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Lauren Diffuse-Type Gastric Adenocarcinoma.

Authors:  Kevin K Chang; Soo-Jeong Cho; Changhwan Yoon; Jun Ho Lee; Do Joong Park; Sam S Yoon
Journal:  Ann Surg Oncol       Date:  2016-06-30       Impact factor: 5.344

Review 4.  Rho GTPases: Anti- or pro-neoplastic targets?

Authors:  I Zandvakili; Y Lin; J C Morris; Y Zheng
Journal:  Oncogene       Date:  2016-12-19       Impact factor: 9.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.